the firm's post-grant practitioners are some of the most experienced in the country.

Diane  Jones
Tao  Feng, Ph.D.
Kevin L. Hartman, Ph.D.
Nanlin  Wang, Ph.D.
Peifang  Tian, Ph.D.
Eckhard H. Kuesters
Thomas M. Cunningham, Ph.D.
Aristotelis M. Psitos
Yorikatsu  Hohokabe, Ph.D.
Ching-Cheng (Tony)  Chang
Brian B. Darville
Aldo  Martinez
Charles L. Gholz
Tia D. Fenton
Johnny  Ma
Eric W. Schweibenz
Kurt M. Berger, Ph.D.
Yin Y. Nelson, Ph.D.
Long  Phan, Ph.D.
Colin B. Harris
Christopher I. Donahue
Jeffrey B. McIntyre
Norman F. Oblon
Frank J. West
Derek  Lightner, Ph.D.
Carl E. Schlier
Vincent K. Shier, Ph.D.
Robert  Tarcu
Alexander B. Englehart
Richard D. Kelly
Chika (Teranishi) Iitoyo
Alec M. Royka
Anna Z. Lloyd
Marina I. Miller, Ph.D.
Grace E. Kim
Nicholas  Rosa, Ph.D.
J. Derek  Mason, Ph.D., CLP
Maki  Saitoh
Jianping (James)  Wu
Robert W. Downs
Ryan W. Smith
Matthew H. Everhart, Ph.D.
Teddy S. Gron
David M. Longo, Ph.D.
Andrew M. Ollis
Yanwen  Fei
Craig R. Feinberg
John S. Kern
Kevin M. McKinley
Stephen G. Baxter, Ph.D.
John F. Presper
Surinder  Sachar
Jay E. Rowe, Jr., Ph.D.
John  Sipos
Yuanyi (Alex) Zhang
Michael R. Casey, Ph.D.
Philippe J.C. Signore, Ph.D.
Soumya  Panda
Edwin D. Garlepp
Kasumi  Kanetaka
Yuki  Onoe
Erik M. Stang, Ph.D.
Elissa L. Sanford
Steven B. Chang
Akihiro  Yamazaki
Stefan Uwe  Koschmieder, Ph.D.
Arthur I. Neustadt
Daniel J. Pereira, Ph.D.
Jenchieh (Joseph) Yuan
Robert T. Pous
Bogdan A. Zinchenko
James R. Love
Christopher  Ricciuti
Dale M. Shaw
Kevin Ross  Davis
Sameer  Gokhale


Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our


Get to know our History

Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our


A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.




From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +

Tokyo Office

Telephone: +81-3-6212-0550
Learn More +


Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Thomas M. Cunningham, Ph.D.

Thomas M. Cunningham, Ph.D.

Senior Attorney ∙ US Office
T: (703) 413-6563
Download My vCard
Download Summary PDF
Download Detailed PDF

Thomas (Tom) M. Cunningham, Ph.D., is a chemical and biotechnology inventions patent attorney in the firm's Chemical Patent Prosecution group. His practice includes drafting and prosecuting patents for chemical and biotechnological inventions for both domestic and foreign clients. A scientist and former Patent Examiner with the United States Patent and Trademark Office (USPTO), Dr. Cunningham also holds an M.B.A. in finance and international business. In his practice, he works with a wide assortment of innovations involving DNA, proteins, antibodies, claims to nutritional products, and chemical aspects of vitamins and food products.

Dr. Cunningham also handles post-grant licensing arrangements, assists clients in developing patent portfolios, devises design-around solutions, and advises on patentability. He regularly conducts studies to determine whether peripheral or new products might be patentable in order to optimize client inventions and cover associated methods, treatments, and diagnostic and other uses that were not originally envisioned. Additionally, he provides infringement and invalidity opinions and represents a diverse range of clients at the USPTO, including before the Board of Patent Appeals and Interferences (BPAI). Representing companies of all sizes, Dr. Cunningham actively participates in U.S. filings and advises on international filings, working in cooperation with local experts on foreign patent systems.

Due to Dr. Cunningham’s scientific background – focused in the areas of microbiology, immunology, molecular genetics, molecular biology and life sciences – he communicates well with inventors, understanding and easily extrapolating the information to develop better and broader patent claims. He has investigated the molecular biology of host/parasite interactions and isolated and purified immunological products. He has also studied molecular genetics and the molecular biology of plants. As a post-doctoral fellow and researcher at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research and the National Institute of Health, he conducted biological research on pathogens, food, nutrition, and food contaminants.

Dr. Cunningham has published numerous articles on molecular biology, disease pathogenesis, electron microscopy, identification of drug-binding proteins, and biochemical fractionation techniques.


  • George Washington University Law School (J.D.)
  • University of California at Los Angeles (Ph.D.)
    • Microbiology & Immunology
  • U.C.L.A. Anderson School of Management (M.B.A.)
    • Finance & International Business
  • Massachusetts Institute of Technology (B.S.)
    • Life Sciences


  • Virginia
  • Registered to practice before the U.S. Patent and Trademark Office


Scientific Publications

  • Selective release of the Treponema pallidum outer membrane and associated olypeptides with Triton X-114.
  • Cunningham TM, Walker EM, Miller JN, Lovett MA.
  • J Bacteriol. 1988 Dec;170(12):5789-96.
  • Identification of Treponema pallidum penicillin-binding proteins.
  • Cunningham TM, Miller JN, Lovett MA.
  • J Bacteriol. 1987 Nov;169(11):5298-300
  • Native surface association of a recombinant 38-kilodalton Treponema pallidum antigen isolated from the Escherichia coli outer membrane.
  • Fehniger TE, Radolf JD, Walfield AM, Cunningham TM, Miller JN, Lovett MA.
  • Infect Immun. 1986 May;52(2):586-93
  • Purification and characterization of a cloned protease-resistant Treponema pallidum-specific antigen.
  • Fehniger TE, Walfield AM, Cunningham TM, Radolf JD, Miller JN, Lovett MA.
  • Infect Immun. 1984 Nov;46(2):598-607
  • Molecular cloning of the major outer membrane protein of Chlamydia trachomatis.
  • Allan I, Cunningham TM, Lovett MA.
  • Infect Immun. 1984 Sep;45(3):637-41.
  • Monoclonal antibodies to surface antigens of a pathogenic Mycoplasma hominis strain.
  • Olson LD, Shane SW, Karpas AA, Cunningham TM, Probst PS, Barile MF. Infect Immun. 1991 May;59(5):1683-9.

Professional Affiliations

  • American Society for Microbiology
  • Virginia Bar Association